Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
Shiv Kumar Sarin(Institute of Liver and Biliary Sciences), Sang Hoon Ahn(Yonsei University), Xiaolong Qi(First Hospital of Lanzhou University), Wan‐Long Chuang(Kaohsiung Medical University), Lau Ing Soo(Hospital Selayang), Shahinul Alam(Bangladesh Medical University), Kemal Fariz Kalista(Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo), Ming‐Hua Zheng(Wenzhou Medical University), Tserendorj Chinbayar(National Center for Communicable Diseases), Ashok Choudhury(Institute of Liver and Biliary Sciences), Masao Omata(The University of Tokyo), Akash Shukla(Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College), Soek-Siam Tan(Hospital Selayang), Oidov Baatarkhuu(Mongolian Academy of Sciences), Mai Khalaf(Tanta University Hospital), Teerha Piratvisuth(Prince of Songkla University), Sherief Abd‐Elsalam(Tanta University Hospital), Jeong Ill Suh(Dongguk University), Uzziel Romar Alonzo(Our Lady of Fatima University), Rino Alvani Gani(University of Indonesia), Wasim Jafri(Aga Khan University), Ian Homer(St. Luke's Medical Center), Badamnachin Batsukh(Mongolian National University of Medical Sciences), Vijay Pal Dara(Yerevan State Medical University), Lovkesh Anand(Manipal Hospital), Dong Ji(Humanity & Health), Chun‐Yu Lin(Uppsala University), Opass Putcharoen(Thai Red Cross Society), Tawesak Tanwandee(Siriraj Hospital), Imelda Maria Loho(Dharmais Cancer Hospital), Salisa Wejnaruemarn(Thai Red Cross Society), Apichat Kaewdech(Prince of Songkla University), Eslam Saber Esmail(Tanta University Hospital), Diana A. Payawal, Soo Young Park(Kyungpook National University Hospital), Jae-Seok Hwang(Keimyung University), George Lau(University of Hong Kong), Hery Djagat Purnomo(Diponegoro University), Osamu Yokosuka(Chiba University), Chang Dong Yeo(Yonsei University), Hitendra Garg(Indraprastha Apollo Hospitals), Pravin Rathi(Topiwala National Medical College & BYL Nair Charitable Hospital), Jun Gi Park(Dongguk University), Arvinder S. Soin(Medanta The Medicity), Sombat Treeprasertsuk(Thai Red Cross Society), Mamun Al Mahtab
Cited by 295
Related Papers
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
|Hepatology International|2017|2.2k
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019
|JAMA Oncology|2021|2k
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
|New England Journal of Medicine|2005|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k